NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's SGX302 Phase 2a Trial Results for Psoriasis Treatment
TL;DR
Soligenix's SGX302 gel shows superior efficacy over its ointment formulation in psoriasis trials, offering investors a potential advantage in the rare disease treatment market.
Soligenix's Phase 2a trial demonstrated SGX302's optimized topical gel formulation improved clinical scores and quality-of-life measures with no drug-related adverse events.
SGX302's non-carcinogenic, non-mutagenic properties could provide a safer therapeutic option for psoriasis patients, improving treatment outcomes and quality of life.
Soligenix's synthetic hypericin gel for psoriasis shows promising results, potentially offering a novel, non-toxic treatment derived from a natural compound.
Found this article helpful?
Share it with your network and spread the knowledge!
This announcement covers extended results from Soligenix's ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) topical gel formulation for treating mild-to-moderate psoriasis.
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, is developing SGX302.
The SGX302 topical gel was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores.
The results from the optimized topical gel formulation were comparable to or exceeded those observed with the prior ointment formulation.
SGX302 is being developed as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis, which could offer a safer alternative to existing treatments.
Soligenix is developing HyBryte™ (SGX301) for cutaneous T-cell lymphoma, dusquetide (SGX942) for inflammatory diseases including oral mucositis, SGX945 for Behcet's Disease, and vaccine candidates for ricin toxin, filoviruses, and COVID-19.
SGX302 is currently in Phase 2a clinical trials for mild-to-moderate psoriasis, with the extended results supporting continued development.
The latest news and updates relating to SNGX are available in the company's newsroom at https://nnw.fm/SNGX.
Soligenix's vaccine programs have been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
NetworkNewsWire is a specialized communications platform that distributed this financial news and content about Soligenix's Phase 2a trial results.
Curated from InvestorBrandNetwork (IBN)
